|
| Study | Sample (T/C) | Mean (T/C) | Intervention | Course of disease | Follow-up | Evaluation |
| T | C | T | C |
|
| Zheng and Guo 2006 [8] | 61.7/63.2 | 97/102 | Pue (Ivgtt) + scopolamine (IV) | Vit B12 (IM) | T2DM (6.7 y) | 4 w | ①④⑤ |
| Wang et al. 2005 [9] | 48 | 62/40 | Pue (Ivgtt) + Mec (Ivgtt) | Mec (Ivgtt) | T2DM + DPN (1–4 m) | 2 w | ①⑤ |
| Huang and Xu 2005 [10] | 53/50 | 37/34 | Pue (Ivgtt) | Anisodamine (Ivgtt) | T2DM (7.6 y) + DPN (2.3 y) | T2DM (8.3 y) + DPN (2.1 y) | 20 d | ① |
| Yu 2002 [11] | 56.2/57.2 | 40/28 | Pue (Ivgtt) + anisodamine (Ivgtt) | Danshen (Ivgtt) | T2DM (11.4 y) + DPN (7.6 y) | T2DM (12 y) + DPN (7.3 y) | 30 d | ①②③④⑤ |
| Tan and Feng 2004 [12] | 58.2/56.3 | 32/32 | Pue (Ivgtt) + Vit B1, B6 (Ivgtt) | Vit B1, B6 (Ivgtt) | DM (10.3 y) + DPN (4.3 y) | DM (11.3 y) + DPN (3.5 y) | 4 w | ①②③④⑤ |
| Yang 2003 [13] | Unclear | 43/40 | Pue (Ivgtt) + Mec (IM) | Vit B12 (IM) | Unclear | Unclear | 12 d | ① |
| Li 2009 [14] | 55/55 | 64/62 | Pue (Ivgtt) + nimodipine (Ivgtt) | Nimodipine (Ivgtt) | DM (3–21 y) + DPN (4 m–6 y) | DM (3–25 y) + DPN (3 m–5 y) | 4 w | ① |
| Wang 2008 [15] | 55/55.5 | 32/31 | Pue (Ivgtt) + nimodipine (Ivgtt) | Nimodipine (Ivgtt) | DM (5–24 y) + DPN (4 m–6 y) | DM (2–25 y) + DPN (3 m–6 y) | 4 w | ① |
| Zhao 2011 [16] | 70.5/38–79 | 40/40 | Pue (Ivgtt) + Mec (Po) | Mec (Po) | DM (6.5 y) + DPN (4.2 y) | DM (2–24 y) + DPN (1–17 y) | 8 w | ① |
| Zhao and Du 2003 [17] | 58.8/No | 36/28 | Pue (Ivgtt) + Mec (Ivgtt) | Mec (Ivgtt) | DM (6–20 y) + DPN (1–11 y) | Unclear | 6 w | ①②③④⑤ |
| Yang et al. 2014 [18] | 56/56 | 29/55 | Pue (Ivgtt) + Mec (Ivgtt) | Mec (Ivgtt) | DM + DPN (9.6 y) | DM + DPN (9.5 y) | 4 w | ①②③④⑤ |
| Chen 2008 [19] | 55/53.5 | 40/38 | Pue (Ivgtt) + alprostadil (Ivgtt) | Alprostadil (Ivgtt) | Unclear | Unclear | 6 w | ① |
| Zhang et al. 2005 [20] | 57.3 | 80/77 | Pue (Ivgtt) + prostaglandin E1 (Ivgtt) | Prostaglandin E1 (Ivgtt) | Unclear | Unclear | 14 d | ① |
| Wang and Wu 2016 [21] | 62.9/63.2 | 41/40 | Pue (Ivgtt) + Epa (Po) | Epa (Po) | T2DM + DPN (12.7 y) | T2DM + DPN (13.0 y) | 2 w | ①②③④⑤ |
| Yu and Tan 2003 [22] | 58.2/58.8 | 32/32 | Pue (Ivgtt) + Mec (IM) | Mec (Ivgtt) | DM (2–10 y) + DPN (5–56 m) | DM (2.5–11.5 y) + DPN (4–50 m) | 20 d | ①②③④⑤ |
| Li and Xu 2003 [23] | 57.2/58.3 | 47/32 | Pue (Ivgtt) + Mec (Ivgtt) | Mec (Po) | DM (10.7 y) + DPN (3.5 y) | DM (8.8 y) + DPN (3.1 y) | 4 w | ①②③④⑤ |
| Li and Wang 2011 [24] | 47/47 | 48/46 | Pue (Ivgtt) + Mec (Ivgtt) | Mec (Ivgtt) | DM (6 m–15 y) + DPN (6 m–5 y) | DM (8–15 y) + DPN (7–5 y) | 6 w | ①③⑤ |
| Lan 2005 [25] | 65.5/64.8 | 36/36 | Pue (Ivgtt) + Mec (Ivgtt) | Danshen (Ivgtt) | DM + DPN (3 y) | DM + DPN (3.1 y) | 6 w | ① |
| Gong 2004 [26] | 53.2/52.7 | 36/32 | Pue (Ivgtt) + Mec (IM) | Mec (IM) | T2DM (10.2 y) + DPN (2.6 y) | T2DM (9.7 y) + DPN (2.7 y) | 8 w | ③⑤ |
| Dou and Wu 2006 [27] | 58.5/57.2 | 28/30 | Pue (Ivgtt) + Epa (Po) | Epa (Po) | DM (6.4 y) + DPN (3.2 y) | DM (5.2 y) + DPN (3.0 y) | 4 w | ①②③④⑤ |
| Peng 2013 [28] | 56.2/57.9 | 40/40 | Pue (Ivgtt) + Epa (Po) | Epa (Po) | T2DM (2–17 y) + DPN (4.1 y) | T2DM (2–18 y) + DPN (4.9 y) | 4 w | ①②③④⑤ |
| Zhou and Wei 2003 [29] | 35–75 | 53/42 | Pue (Ivgtt) | Vit B1, B12 (IM) | Unclear | Unclear | 30 d | ①②④⑤ |
| Chen et al. 2003 [30] | 57.1/57 | 40/40 | Pue (Ivgtt) | Vit B1, B12 (IM) | Unclear | Unclear | 4 w | ①②③④⑤ |
| Liao and Chen 2008 [31] | 64 | 21/21 | Pue (Ivgtt) | Vit B1, B12 (IM) | Unclear | Unclear | 2 w | ① |
| Ma et al. 2001 [32] | 58/55 | 21/20 | Pue (Ivgtt) | Vit B1 (Po) + Vit B12 (IM) | DM + DPN (13 y) | DM + DPN (15 y) | 15 d | ① |
| Zhu 2013 [33] | 61.3 | 31/31 | Pue (Ivgtt) | Vit B | Unclear | Unclear | 4 w | ① |
| Chen and Tang 2001 [34] | 56/54 | 32/20 | Pue (Ivgtt) + Vit B1, B6 (IM) | Vit B1, B12 (IM) | DM (8.6 y) + DPN (7.2 y) | DM (9 y) + DPN (8 y) | 20 d | ① |
| Yang 2010 [35] | 58.6/58.4 | 21/21 | Pue (Ivgtt) + Mec (Po) | Mec (Po) | Unclear | Unclear | 1 m | ①②④⑤ |
| Zhu 2009 [36] | 59.6/60.3 | 25/24 | Pue (Ivgtt) + α-lipoic acid (Ivgtt) | Pue (Ivgtt) | T2DM (11.9 y) | T2DM (11.6 y) | 2 w | ①②③④⑤ |
| Zhu et al. 2001 [37] | 54/56 | 50/42 | Pue (Ivgtt) | Vit B12 (I.M.) | DM (144 m) + DPN (28.3 m) | DM (132 m) + DPN (30.4 m) | 20 d | ①②③④ |
| Zhong 2011 [38] | 55/54 | 65/54 | Sodium ozagrel (Ivgtt) + Pue (Ivgtt) | Vit B1, B12 (IM) | DM (4 y) | DM (3.9) | 14 d | ②④ |
| Mo and Wang 2012 [39] | 65.4/66.2 | 30/30 | Pue (Ivgtt) + Mec (Po) | Pue (Ivgtt) | Unclear | Unclear | 2 w | ① |
| Zhang 2007 [40] | 62/60 | 30/30 | Pue (Ivgtt) + Mec (IM) | Mec (I.M.) | T2DM (12.3 y) + DPN (4.3 y) | T2DM (11.6 y) + DPN (3.9 y) | 4 W | ①②③④⑤ |
| Yang and Zhang 2008 [41] | 58.6/59.6 | 45/45 | Pue (Ivgtt) + Mec (Po) | Mec (Po) | T2DM (9.7 y) | T2DM (10.0 y) | 4 w | ① |
| Yang and Li 2012 [42] | 57.2 | 23/23 | Pue (Ivgtt) | Conventional therapy | Unclear | Unclear | 2 w | ① |
| Dong and Ge 2015 [43] | 46.4/45.6 | 43/43 | Pue (Ivgtt) + Vit B1, B12 | Vit B1, B12 | Unclear | Unclear | 4 w | ②③④⑤ |
| Zhang 2017 [44] | 61/59.4 | 32/30 | Pue (Ivgtt) + Vit B1, B12 (IM) | Vit B1, B12 (IM) | Unclear | Unclear | 14 d | ①②③④⑤ |
| Lin et al. 2000 [45] | 58.4/56.9 | 66/22 | Pue (Ivgtt) + Vit B1, B12 (IM) | Mec (Po) + Vit B1, B12 (IM) | DM (12.8 y) + DPN (4.2 y) | DM (11.6 y) + DPN (3.9 y) | 60 d | ①②③④⑤ |
| Tan 2001 [46] | 55.6/56.2 | 47/38 | Pue (Ivgtt) + Vit B | Vit B | DM (1–21 y) + DPN (1 m–10 y) | DM (1–20 y) + DPN (1 m–8 y) | 60 d | ① |
| Zhu and Quan 2000 [47] | Unclear | 33/32 | Pue (Ivgtt) | Danshen (Ivgtt) | Unclear | Unclear | 3 w | ① |
| T. He and Y. L. He 2002 [48] | 56 | 36/40 | Pue (Ivgtt) | Danshen (Ivgtt) | Unclear | Unclear | 6 w | ① |
| Zhang 2011 [49] | 53.3/54.5 | 28/29 | Pue (Ivgtt) + Vit B1, B12 | Vit B1, B12 | T2DM (6.5 y) | T2DM (6.8 y) | 3 w | ① |
| Song and Xu 2000 [50] | 17–82 | 33/29 | Pue (Ivgtt) + Mec (IM) | Vit B1, B12 | Unclear | Unclear | 4–8 w | ① |
| Wang 2007 [51] | 58.9/59.4 | 48/46 | Pue (Ivgtt) + Mec (Po) | Mec (Po) | T2DM (15.6 y) + DPN (8.9 y) | T2DM (16.2 y) + DPN (8.7 y) | 3 m | ①②③④⑤ |
| Feng et al. 2004 [52] | 58.2/56.3 | 32/32 | Pue (Ivgtt) + Mec (Ivgtt) + Vit B1, B6 (Ivgtt) | Mec (Ivgtt) + Vit B1, B6 (Ivgtt) | T2DM (10.3 y) + DPN (4.3 y) | T2DM (11.3 y) + DPN (3.8 y) | 4 w | ①②③④⑤ |
| Hu and Li 2006 [53] | 48 | 60/40 | Pue (Ivgtt) | Vit B1, B12 (IM) | Unclear | Unclear | 2 w | ① |
| Zuo 2004 [54] | 56.5 | 21/22 | Pue (Ivgtt) | Danshen (Ivgtt) | Unclear | Unclear | 3 m | ①③⑤ |
| Bai 2005 [55] | 55.3/57.4 | 50/30 | Pue (Ivgtt) | Conventional therapy | DM (11.8 y) + DPN (6.6 y) | DM (12.5 y) + DPN (7.1 y) | 4 w | ①②③④⑤ |
| Li 2005 [56] | 42.9/43.2 | 60/30 | Pue (Ivgtt) + anisodamine (Ivgtt) | Anisodamine (Ivgtt) | DM + DPN (6.7 y) | DM + DPN (7.1 y) | 3 w | ②③④⑤ |
| Mao 2006 [57] | 54 | 32/20 | Pue (Ivgtt) + Mec (IM) | Mec (IM) | Unclear | Unclear | 4 w | ①②③④⑤ |
| Yang 2016 [58] | 54.36/54.1 | 40/40 | Pue (Ivgtt) + Vit B1, B6 (IM) | Vit B1, B6 (IM) | DM + DPN (8.24 y) | DM + DPN (8.10 y) | 2 m | ① |
| Peng and Ren 2005 [59] | Unclear | 60/60 | Pue (Ivgtt) | Conventional therapy | DM + DPN (4–16 y) | DM + DPN (4–22 y) | 1 m | ①④⑤ |
| Dong 2015 [60] | 54.18/55.3 | 40/41 | Pue (Ivgtt) | Conventional therapy | Unclear | Unclear | 2 m | ①②③④⑤ |
|
